Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of metformin powder in China. Welcome to wholesale bulk high quality metformin powder for sale here from our factory. Good service and reasonable price are available.
Metformin Powder is the pure powder form of metformin, with the chemical name 1,1-dimethylbiguanide, molecular formula C ₄ H ₁₁ N ₅, and molecular weight of 129.16 g/mol. The appearance is usually white to light yellow crystalline powder, easily soluble in water, stable under acidic conditions, but may decompose in strongly alkaline environments. It needs to be stored away from light and moisture to prevent degradation or deterioration. It inhibits the mitochondrial respiratory chain in the liver, reduces glucose output, activates AMPK (adenosine monophosphate activated protein kinase), and enhances glucose uptake and utilization in muscle and adipose tissue. Reduce the absorption efficiency of glucose in the intestine and further control blood sugar levels. Metformin may inhibit the proliferation and metastasis of tumor cells, reduce the risk of cardiovascular events and improve the survival rate of patients with diabetes by regulating cell metabolism and signal pathways.
Additional information of chemical compound:
| Product Name | Metformin Powder | Metformin Tablet | Metformin Capsule | Metformin Cream | Metformin Solution |
| Product Type | Powder | Tablet | Capsules | lotion | liquid |
| Product Purity | ≥99% | ≥99% | ≥99% | ≥99% | ≥99% |
| Product Specifications | 100g/1kg/etc. | 0.5g/250mg/500mg | 0.25g | 10g/15g | 500mg/5mL |
| Product Form | Organic synthesis | Take Orally | Take Orally | External application | External application |
|
|
|
Metformin COA
 |
|
|
|
|
Metformin Powder is the pure powder form of metformin. As the most widely used oral hypoglycemic drug in the world, its use has expanded from traditional diabetes treatment to multi field health management. The following is a detailed explanation of its purpose:
Core clinical use: first-line treatment of type 2 diabetes
Hypoglycemic mechanism: multi-target synergistic effect
Metformin lowers blood sugar through a triple mechanism of inhibiting liver glucose production, increasing peripheral tissue (such as muscle and fat) sensitivity to insulin, and reducing intestinal glucose absorption. Its unique feature is that it does not stimulate insulin secretion, so it rarely causes hypoglycemia when used alone, especially for obese type 2 diabetes patients.
Liver inhibition: By activating AMP activated protein kinase (AMPK), the expression of key gluconeogenic enzymes such as phosphoenolpyruvate carboxykinase and glucose-6-phosphatase is inhibited, reducing hepatic glucose output.
Peripheral utilization: promotes anaerobic fermentation of glucose by muscle cells and increases glucose uptake; Improve insulin resistance in adipose tissue and reduce levels of free fatty acids.
Intestinal regulation: Delaying intestinal glucose absorption and potentially indirectly improving metabolism by altering gut microbiota composition (such as increasing short chain fatty acid producing bacteria).
Clinical Evidence: The Preferred Recommendation for Global Guidelines
Efficacy confirmation: UKPDS study (British prospective study on diabetes) confirmed that metformin can reduce the all-cause mortality of diabetes patients by 32%, the risk of myocardial infarction by 39%, and its cardiovascular protection is better than sulfonylureas and insulin.
Applicable population: It covers overweight/obese and non obese type 2 diabetes patients, especially for newly diagnosed patients, elderly patients and those with metabolic syndrome.
Combination therapy: Combining with sulfonylureas, DPP-4 inhibitors, SGLT-2 inhibitors, or insulin can significantly enhance hypoglycemic effects and reduce insulin dosage (average reduction of 20% -30%).
Formulation advantage: flexibility in powder form
Metformin powder can be applied in the following ways:
Formulation production: used for tablet pressing, capsule filling, or compound formulation to meet different dosage requirements (such as 250mg, 500mg, 850mg).
Personalized administration: For patients with swallowing difficulties, it can be formulated as a suspension or mixed with food for administration; In scientific research, precise dose control can be used to study dose-response relationships.
Special population: Children can adjust the dosage according to their weight (usually 10-15mg/kg per day), and the powder form is easy to package.
Research Applications: From Basic Research to Drug Development
Pharmacological mechanism research model
Metformin powder is an ideal tool for exploring its multi-target effects:
Cell experiments: used to study its effects on mitochondrial function (such as inhibition of complex I), AMPK pathway, mTOR signaling, and gut microbiota metabolism. For example, a study by Northwestern University found that metformin reduces ATP synthesis and activates AMPK by targeting mitochondrial complex I, thereby inhibiting hepatic glucose production.
Animal model: In diabetes mice, obese rats and tumor transplantation models, the powder can be prepared into solutions of different concentrations for oral administration or intraperitoneal injection to observe its dynamic effects on blood sugar, body weight and tumor growth.
New indication development platform
The powder form facilitates the following research:
Antitumor effect: Metformin can inhibit the proliferation of colorectal cancer, lung cancer, prostate cancer and other cells, and its mechanism involves downregulating miR-222-3p, upregulating miR-2110 and other microRNA expression, and blocking the progression of tumor cell cycle.
Anti aging research: In online insect and mouse models, metformin activates AMPK and extends lifespan by 10% -20% by simulating calorie restriction effects. The powder form is convenient for long-term administration and dosage adjustment.
Neuroprotection: As a blood-brain barrier penetrative AMPK activator, metformin may improve metabolic disorders in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Drug interaction research
The powder form can precisely control the proportion of combination therapy, for example:
Combined with EGFR-TKI: In clinical studies of non-small cell lung cancer, metformin (500mg bid) combined with gefitinib significantly increased the objective response rate (ORR) from 34% to 58% and prolonged progression free survival (PFS) from 9.8 months to 13.1 months.
Combination with SGLT-2 inhibitors: Metformin combined with empagliflozin can synergistically reduce HbA1c by 1.5% -2.0%, while reducing the risk of cardiovascular events.
Expansion of special indications: from diabetes to systemic disease management
Reproductive endocrine field
Polycystic ovary syndrome (PCOS): Metformin can improve insulin resistance, reduce androgen levels, and restore ovulation cycle. Research has shown that its combination with clomiphene can increase ovulation rate to 80% and pregnancy rate to 30% in PCOS patients.
Gestational diabetes (GDM): FDA approved metformin for GDM in 2016, and its powder form can be prepared into a low-dose solution to reduce gastrointestinal side effects. Research has shown that the combination of metformin and insulin can reduce weight gain in pregnant women (average reduction of 2.3kg) and the risk of neonatal hypoglycemia.
Dermatology applications
Acne: Metformin improves hyperandrogenism related acne by inhibiting androgen synthesis and mTOR pathway. A study on 40 women with PCOS complicated with acne showed that after 8 weeks of oral metformin (500mg tid), the severity score of acne decreased by 60%.
Non melanoma skin cancer (NMSC): Recent research has confirmed that metformin can reduce the risk of basal cell carcinoma (BCC) by 42% and squamous cell carcinoma (SCC) by 18%. Its mechanism is related to reducing UV induced DNA damage and inhibiting the hedgehog signaling pathway.
Wound healing: The thermosensitive hydrogel made of metformin and zinc coordination complex (ZnMet) can promote the healing of diabetes ulcer, which reduces the risk of oxidative stress and infection by activating AMPK and autophagy.
Cardiovascular protection
Atherosclerosis: Metformin can reduce low-density lipoprotein cholesterol (LDL-C) 0.5-1.0 mmol/L, reduce the expression of vascular endothelial inflammatory factors (such as IL-6, TNF - α), and delay the progression of atherosclerosis.
Heart failure: In diabetes patients with heart failure, metformin can reduce all-cause mortality by 25%, and its mechanism is related to improving myocardial energy metabolism and reducing lactic acid accumulation.
Adjuvant treatment of COVID-19
Preliminary research shows that metformin may improve the prognosis of patients with COVID-19 through the following mechanisms:
Inhibition of virus replication: In vitro experiments have shown that metformin (10mM) can inhibit the replication of SARS-CoV-2 in Caco-2 cells, with an IC50 value of 1.43mM.
Regulating immune response: reducing the release of pro-inflammatory cytokines (such as IL-6, IL-1 β) to prevent cytokine storms.
Improve metabolic disorder: correct COVID-19 related hyperglycemia and hyperinsulinemia, and reduce the risk of thrombosis.
Safety and usage precautions
Common side effects
Gastrointestinal reactions: About 20% -30% of patients experience nausea and diarrhea during the initial treatment period. It is recommended to start with a small dose (500mg/d) and gradually increase the dose to an effective dose (1500-2000mg/d).
Vitamin B12 deficiency: Long term use (>4 years) may increase the risk of vitamin B12 deficiency (about 10%). It is recommended to monitor serum B12 levels annually and supplement if necessary.
Lactic acidosis: rare but severe, with an incidence rate of about 0.03/1000 person years, commonly seen in patients with renal insufficiency (eGFR<30mL/min/1.73m ²), heart failure, or severe infections, and strict screening for contraindications is necessary.
Medication for special populations
Elderly: Adjust the dosage according to eGFR, with a maximum dose of 1000mg/d at eGFR 45-59mL/min/1.73m ²; Disable when eGFR<45mL/min/1.73m ².
Children: Suitable for patients over 10 years old, with a maximum dose of 2000mg/d. Blood glucose and growth and development indicators need to be monitored.
Pregnant and lactating women: GDM patients can use it for a short period of time; Breastfeeding women need to weigh the pros and cons, as metformin can be secreted into breast milk (at a concentration of approximately 50% of maternal blood).
The pace of science entered the 19th century, and chemists began to attempt to decipher the pharmacological basis of goat beans. In 1914, chemist George Tanret, working in Dublin, Ireland, successfully isolated an alkaloid from goat beans and named it "Galegine". Subsequent structural identification revealed that goat bean alkaloid is an isopentenyl substituted guanidine derivative.
The chemical structure of guanidine became the core of the story. Guanidine itself is a strongly alkaline molecule composed of three nitrogen atoms connected to a central carbon atom. Scientists quickly discovered that simple guanidine itself has a strong hypoglycemic effect, but its toxicity is too high to be used for clinical treatment. This discovery brings both hope and obstacles: hope lies in identifying the chemical mother nucleus of hypoglycemic activity; The obstacle lies in the need to structurally modify guanidine in order to find derivatives with lower toxicity and higher safety.
In 1921, Frederick Banting and Charles Best discovered insulin. This epoch-making achievement, like the dazzling sun, instantly lit up the dark sky of diabetes treatment, and almost completely obscured the light of research in other directions. Insulin can quickly save the lives of patients with ketoacidosis, and its dramatic effects have almost entirely focused the scientific community's attention on hormone replacement therapy. The idea of using oral chemical drugs to gently control blood sugar has been overshadowed and outdated for a while.
In 1922, Irish scientists Emil Werner and James Bell first synthesized metformin (then called "Ziding essence"). At the same time, other biguanide compounds such as Phenformin and Buforin were also synthesized successively.
Throughout the 1920s and 1940s, multiple animal experiments and a small number of human studies successively confirmed the clear hypoglycemic effect of biguanide compounds, especially metformin.
Hot Tags: metformin powder, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale, 4 Fluorotropacocaine, levamisole hydrochloride powder, lidocaine hydrochloride powder, paracetamol powder, Procaine Hydrochloride, pure aspirin powder